StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Belsomra (suvorexant by Year

Belsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%) (%)

Merck Belsomra (suvorexant: -16.0% in FY2025, down 12.0 pts from a year earlier.

Latest, FY2025
-16.0%
Period ended Dec 31, 2025
Change on a year earlier
-12.0 pts
-4.0% in FY2024
History
7 years
Since FY2018
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Belsomra | 186 | 222 | -16 | 82 | 72 | 13 | 104 | 150 | -31”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBelsomra (suvorexant — insomnia orexin receptor antagonist) — Worldwide reported growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-16.0%-12.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024-4.0%+7.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023-11.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 2021-3.0%-10.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 20207.0%-11.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2019Dec 31, 201918.0%-6.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 201824.0%–Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Cite this data

StockData. (2026). Merck Belsomra (suvorexant (%), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-belsomra-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.